Genomics-driven drug discovery based on disease-susceptibility genes
نویسندگان
چکیده
منابع مشابه
Function-driven discovery of disease genes in zebrafish using an integrated genomics big data resource
Whole exome sequencing (WES) accelerates disease gene discovery using rare genetic variants, but further statistical and functional evidence is required to avoid false-discovery. To complement variant-driven disease gene discovery, here we present function-driven disease gene discovery in zebrafish (Danio rerio), a promising human disease model owing to its high anatomical and genomic similarit...
متن کاملStructural genomics and drug discovery
Structure determination has already proven useful for lead optimization and direct drug design. The number of high-resolution structures available in public databases today exceeds 30,000 and will definitely aid in structure-based drug design. Structural genomics approaches covering whole genomes, topologically similar proteins or gene families are great assets for further progress in the devel...
متن کاملGenomics in target and drug discovery.
Genomics-based discovery of novel therapeutic drug targets requires the design of well-controlled biological or pharmacological experiments with experimental questions and hypotheses that relate to the therapeutic area of interest. This will aid the validation level of differentially expressed genes and hence facilitate the de-selection of the genes that are identified in microarray experiments...
متن کاملGenomics and transcriptomics in drug discovery.
The popularization of genomic high-throughput technologies is causing a revolution in biomedical research and, particularly, is transforming the field of drug discovery. Systems biology offers a framework to understand the extensive human genetic heterogeneity revealed by genomic sequencing in the context of the network of functional, regulatory and physical protein-drug interactions. Thus, app...
متن کاملAccelerating Drug Discovery and Development Using Genomics
Despite the continuing advancements in the treatment of cancer and the introduction of new therapies, responses still vary from patient to patient. In many cases, this variation remains unexplained, making it difficult to predict who will respond. For instance, immunotherapies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and the PD-1 li...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammation and Regeneration
سال: 2021
ISSN: 1880-8190
DOI: 10.1186/s41232-021-00158-7